Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematologic neoplasm characterized by the expression of the BCR::ABL1 oncoprotein, a constitutively active tyrosine kinase, resulting in uncontrolled growth and proliferation of cells in the myeloid lineage. Targeted therapy using tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhagen, Noor E., Koenderink, Jan B., Blijlevens, Nicole M. A., Janssen, Jeroen J. W. M., Russel, Frans G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675650/
https://www.ncbi.nlm.nih.gov/pubmed/38004514
http://dx.doi.org/10.3390/pharmaceutics15112535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675650/
https://www.ncbi.nlm.nih.gov/pubmed/38004514
http://dx.doi.org/10.3390/pharmaceutics15112535

Ejemplares similares